|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
10/10/2012 8:07:29 AM
Major drug makers such as Aventis Pharma, Ind-Swift, Aurobindo Pharma and Ipca Laboratories have been listed for overcharging while selling some essential medicines. The drug price regulator, National Pharmaceutical Pricing Authority (NPPA), has issued showcause notices to all these, an official told Business Standard. According to the NPPA list for the current year, reviewed by Business Standard, Aventis Pharma, the Indian arm of Sanofi-Aventis, overcharged consumers for Avil (25 mg and 50 mg) and Combiflam. While the latter is commonly used as a painkiller and to reduce fever, Avil is an antihistamine used to treat allergic conditions such as hay fever. When approached, Sanofi-Aventis said: “We do not have any comments to share.” Besides, notices have been sent to Ind-swift for overcharging for Provita, Neurovit; Aurobindo Pharma for Z Plus; and Z Clox and Ipca Labs for Normax TZ.
|
|
|
|
|
|
|
|
|
|
|